GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

bremelanotide

Company
Palatin Technologies, Inc
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00425256

    Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

    Not yet reported Palatin Technologies, Inc Est. completion 2007-05 20 sites
    Other conditions: Sexual Arousal Disorder
    View official trial listing →
  • Completed NCT NCT01382719

    Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

    Not yet reported Palatin Technologies, Inc 612 participants Est. completion 2012-09 68 sites Stand-alone
    Other conditions: Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
    View official trial listing →
  • Completed NCT NCT02333071

    1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

    Not yet reported Palatin Technologies, Inc 723 participants Est. completion 2017-06-30 91 sites Stand-alone
    Other conditions: Hypoactive Sexual Desire Disorder
    View official trial listing →
  • Completed NCT NCT02338960

    2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

    Not yet reported Palatin Technologies, Inc 714 participants Est. completion 2017-06-29 91 sites Stand-alone
    Other conditions: Hypoactive Sexual Desire Disorder
    View official trial listing →
  • Completed NCT NCT03973047

    Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

    Not yet reported AMAG Pharmaceuticals, Inc. 228 participants Est. completion 2019-07-20 1 site
    Other conditions: Nausea
    View official trial listing →
  • Completed NCT NCT04179734

    Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

    Not yet reported Imperial College Healthcare NHS Trust 40 participants Est. completion 2020-10-06 1 site Stand-alone
    Other conditions: Hypoactive Sexual Desire Disorder
    View official trial listing →
  • Completed NCT NCT04943068

    A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

    Not yet reported Kwang Dong Pharmaceutical co., ltd. 193 participants Est. completion 2023-05-16 1 site Stand-alone
    Other conditions: Hypoactive Sexual Desire Disorder
    View official trial listing →
  • Completed NCT NCT05709444

    A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

    Not yet reported Palatin Technologies, Inc 16 participants Est. completion 2024-04-26 9 sites Stand-alone
    Other conditions: Kidney Disease
    View official trial listing →
  • Active, not recruiting NCT NCT06565611

    A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

    Not yet reported Palatin Technologies, Inc 108 participants Est. completion 2025-03-31 4 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT06867835

    Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

    Not yet reported Cosette Pharmaceuticals, Inc. 10 participants Est. completion 2025-11-15 1 site Stand-alone
    Other conditions: Lactating Mother
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.